The natural history of treated PD in an incident, community-based cohort: does the future begin?

Advances in our understanding of the genetics, epidemiology, clinical phenotype and pathological progression of Parkinson’s disease (PD) have ushered in an era in which researchers are increasingly looking for therapies that modify (prevent or delay) PD course. Drugs like levodopa, selegiline and rasagiline, which are known to ameliorate the core motor symptoms of PD, have been tested for a possible disease-modifying effect,1–3 and new putative neuroprotective therapies could soon be available.

In order to accurately test neuroprotective effects, drugs need to be challenged with markers of disease progression. To date, data from putative biomarkers assessed in body fluids are limited and inconclusive, structural imaging does not add relevant information to our knowledge and imaging techniques that enable assessment of the nigrostriatal dopaminergic system (like dopamine transporter single photon emission CT) might not sufficiently mirror disease progression owing to possible confounding by dopaminergic medication.<cross-ref…

http://jnnp.bmj.com/cgi/content/short/82/10/1065?rss=1



Categories: Uncategorized

Tags:

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: